Serina Therapeutics, Inc 10-K for FY2022

Serina Therapeutics, Inc. (SER)

10-K 2023-03-31 For: 2022-12-31

Added on April 09, 2026

About this 10-K

Serina Therapeutics, Inc filed this 10-K on March 31, 2023, covering the fiscal year ended December 31, 2022 (FY2022).

Headline figures

Fiscal year ended December 31, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $34K; down 76.4% from $144K a year earlier
Net loss: $10.46M; compared with a net loss of $8.68M a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, par value $0.0001 per share		AGE		NYSE American

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☒

			Page Number
Part I
	Item 1.	Business	6
	Item 1A.	Risk Factors	30
	Item 1B.	Unresolved Staff Comments	61
	Item 2.	Properties	61
	Item 3.	Legal Proceedings	61
	Item 4.	Mine Safety Disclosures	61

Part II
	Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	62
	Item 6.	Selected Financial Data	62
	Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	62
	Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	71
	Item 8.	Financial Statements and Supplementary Data	72
	Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	107
	Item 9A.	Controls and Procedures	107
	Item 9B.	Other Information	107
	Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	107

Part III
	Item 10.	Directors, Executive Officers, and Corporate Governance	108
	Item 11.	Executive Compensation	110
	Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	116
	Item 13.	Certain Relationships and Related Transactions, and Director Independence	117
	Item 14.	Principal Accounting Fees and Services	123

Part IV
	Item 15.	Exhibits and Financial Statement Schedules	124
	Item 16.	Form 10-K Summary	129

Signatures			130

	●	the amount of capital that we will have for our development programs and our projected costs for those programs;

	●	our ability to enter into licensing or collaborative arrangements with other biotechnology or biopharma companies or universities with their own laboratory facilities and research staffs to conduct research and development of one or more product candidates;

	●	competitors may develop alternatives that render our potential product candidates obsolete or less attractive;

	●	potential product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;

	●	potential product candidates may not be effective in treating their targeted diseases;

	●	potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;

	●	our analysis of market demand and market prices for the products we plan to develop could lead us to conclude that market conditions are not favorable for receiving an adequate return on our investment in product development and commercialization;

	●	a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or

	●	the regulatory pathway for a potential product candidate is too complex and difficult to navigate successfully or economically.

	●	the efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;

	●	the prevalence and severity of the disease and any side effects;

	●	the clinical indications for which approval is granted, including any limitations or warnings contained in a product’s approved labeling;

	●	the convenience and ease of administration;

	●	the cost of treatment, particular as additive to existing treatments;

	●	the willingness of the patients and physicians to accept and use these therapies and the perception of efficacy and safety of our approved products by such parties;

	●	the marketing, sales and distribution support for the products;

	●	the publicity and ethical, social and legal concerns regarding the use of embryonic stem cells for our products or competing products and treatments;

	●	government regulations restricting or prohibiting our research or manufacturing processes for stem cells due to ethical, social and legal concerns regarding their use in medical research and treatment; and

	●	the pricing and availability of third-party insurance coverage and reimbursement.

	●	Our estimates have been derived from a variety of sources, including publications and scientific literature or market research estimating the total number of patients and currently approved or used therapies, as well as certain assumptions regarding the potential size of the market assuming broad regulatory approval or potential usage by physicians beyond the approved label, any of which may prove to be incorrect.

	●	The scope of approval and potential use may be significantly narrower, and the number of patients may turn out to be lower than expected.

	●	Competitive products or approaches may be approved or come into use by medical providers and the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, any which could adversely affect our results of operations and our business.

	●	We or any third-party manufacturers might be unable to timely formulate and manufacture our products or produce the quantity and quality required to meet our clinical and commercial needs, if any.

	●	We or any third-party manufacturers may not be able to execute our manufacturing procedures appropriately.

	●	Any third-party manufacturers we engage may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products on a commercial scale.

	●	We or any third-party manufacturers will be subject to ongoing periodic unannounced inspection by the FDA, and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We will not have control over third-party manufacturers’ compliance with applicable regulations and standards.

	●	We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates.

	●	Third-party manufacturers could breach or terminate their agreements with us.

	●	We or third-party manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments.

	●	Expensive and time-consuming clinical trials of new products will need to be conducted. The full cost of conducting and completing clinical trials necessary to obtain FDA and foreign regulatory approval of a new product cannot be presently determined but could exceed our financial resources or could discourage any future licensees or collaborators from pursuing FDA approval of our product candidates.

	●	Clinical trials and the regulatory approval process for a pharmaceutical or cell-based product can take several years to complete. As a result, we will face expenses and delays inherent in seeking FDA and foreign regulatory approval of new products, even if the results of clinical trials are favorable.

	●	Data obtained from preclinical and clinical studies is susceptible to varying interpretations and regulatory changes that could delay, limit, or prevent regulatory agency approvals.

	●	Because the therapeutic products we plan to develop with pluripotent stem cell technology or progenitor cell technology involve the application of new technologies and approaches to medicine, the FDA or foreign regulatory agencies may subject those products to additional or more stringent review than drugs or biologicals derived from other technologies.

	●	A product that is approved may be subject to restrictions on use.

	●	The FDA can recall or withdraw approval of a product, if it deems necessary.

	●	We will face similar regulatory issues in foreign countries.

	●	The FDA or comparable foreign regulatory authorities may disagree with the design or implementation of the applicable clinical trial;

	●	A clinical trial might not demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;

	●	The results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;

	●	A clinical trial fail to demonstrate that our product candidates’ clinical and other benefits outweigh their safety risks;

	●	The FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical programs or clinical trials;

	●	The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;

	●	The facilities of the any third-party manufacturers with which we may contract may not be adequate to support approval of our product candidates (for example, regulatory approval of cell- and tissue-based products require high standards of quality control); and

	●	The approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

	●	the size of the patient population required for analysis of the trial’s primary endpoints;

	●	the proximity of patients to study sites;

	●	the design of the trial;

	●	our ability to recruit clinical trial investigators with the appropriate competencies and experience;

	●	clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;

	●	our ability to obtain and maintain patient consents; and

	●	the risk that patients enrolled in clinical trials will drop out of the trials before completion.

	●	inability to generate satisfactory preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical studies necessary for product approval;

	●	delays in reaching agreement on acceptable terms with clinical research organizations or CROs and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;

	●	delays in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;

	●	failure to permit the conduct of a study by regulatory authorities, after review of an investigational new drug, or IND, or equivalent foreign application or amendment;

	●	delays in recruiting qualified patients in our clinical studies;

	●	failure by clinical sites or our CROs or other third parties to adhere to clinical study requirements or report complete findings;

	●	failure to perform the clinical studies in accordance with the FDA’s good clinical practices requirements, or applicable foreign regulatory guidelines;

	●	patients dropping out of our clinical studies;

	●	occurrence of adverse events associated with our product candidates;

	●	inability to use clinical trial results from foreign jurisdictions in support of U.S. regulatory approval;

	●	changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;

	●	the cost of clinical studies of our product candidates;

	●	negative or inconclusive results from our clinical trials which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon development programs for a product candidate; and

	●	delays in reaching agreement on acceptable terms with third-party manufacturers, or delays in the manufacture of sufficient quantities of our product candidates for use in clinical studies.

	●	restrictions on the labeling or marketing of a product;

	●	restrictions on product distribution or use;

	●	requirements to conduct post-marketing studies or clinical trials;

	●	warning letters or holds on clinical trials;

	●	withdrawal of the products from the market;

	●	refusal to approve pending applications or supplements to approved applications that we submit;

	●	recall of products;

	●	fines, restitution or disgorgement of profits or revenues;

	●	suspension or withdrawal of marketing approvals;

	●	refusal to permit the import or export of our products;

	●	product seizure or detention; or

	●	injunctions or the imposition of civil or criminal penalties.

	●	regulatory authorities may withdraw approvals of such product;

	●	we may be required to recall a product or change the way such product is administered to patients;

	●	additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product;

	●	regulatory authorities may require additional warnings on the label, such as a “black box” warning or contraindication;

	●	we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;

	●	the product could become less competitive;

	●	we could be sued and held liable for harm caused to patients; and

	●	our reputation may suffer.

	●	impairment of our business reputation;

	●	initiation of investigations by regulators;

	●	withdrawal of clinical trial participants;

	●	costs due to related litigation;

	●	distraction of management’s attention from our primary business;

	●	substantial monetary awards to patients or other claimants;

	●	the inability to commercialize our product candidates;

	●	product recalls, withdrawals or labeling, and marketing or promotional restrictions;

	●	loss of revenue; and

	●	decreased demand for our product candidates, if approved for commercial sale.

	●	an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;

	●	new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting “transfers of value” made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members;

	●	a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;

	●	expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;

	●	a licensure framework for follow on biologic products;

	●	a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and

	●	establishment of a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

	●	new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements;

	●	changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;

	●	requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA’s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception, or legal action which could harm our business; and

	●	changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.

	●	the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;

	●	federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;

	●	the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

	●	HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and implementing regulations, which impose certain requirements relating to the privacy, security, and transmission of individually identifiable health information;

	●	the Physician Payments Sunshine Act which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;

	●	the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;

	●	the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; and

	●	state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payors, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances.

	●	a collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale or downsizing;

	●	a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;

	●	a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration;

	●	a collaboration partner may not devote sufficient capital or resources towards our product candidates;

	●	a collaboration partner may change the success criteria for a product candidate thereby delaying or ceasing development of such candidate;

	●	a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;

	●	a collaboration partner could develop a product that competes, either directly or indirectly, with our product candidate;

	●	a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;

	●	a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;

	●	a collaboration partner may terminate a strategic alliance;

	●	a dispute may arise between us and a partner concerning the research, development or commercialization of a product candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and

	●	a partner may use our products or technology in such a way as to invite litigation from a third party.

	●	Our success will depend in part on our ability to obtain and enforce patents and maintain trade secrets in the United States and in other countries. If we are unsuccessful in obtaining and enforcing patents, our competitors could use our technology and create products or technologies that compete with our products and technologies, without paying license fees or royalties to us.

	●	The preparation, filing, and prosecution of patent applications can be costly and time consuming. Our limited financial resources may not permit us to pursue patent protection of all of our technology and products throughout the world.

	●	Even if we are able to obtain issued patents covering our technology or products, we may have to incur substantial legal fees and other expenses to enforce our patent rights in order to protect our technology and products from infringing uses. We may not have the financial resources to finance the litigation required to preserve our patent and trade secret rights.

	●	The preparation and filing of patent applications, and the maintenance of patents that are issued, may require substantial time and money.

	●	A patent interference proceeding may be instituted with the U.S. Patent and Trademark Office (the “USPTO”) when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity of an issued patent. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitled to the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings, and the USPTO’s decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patent applications, we may experience significant expenses and delay in obtaining a patent, and if the outcome of the proceeding is unfavorable to us, the patent could be issued to a competitor rather than to us.

	●	A derivation proceeding may be instituted by the USPTO or an inventor alleging that a patent or application was derived from the work of another inventor.

	●	Post Grant Review under the new America Invents Act will make available opposition-like proceedings in the United States. As with the USPTO interference proceedings, Post Grant Review proceedings will be very expensive to contest and can result in significant delays in obtaining patent protection or can result in a denial of a patent application.

	●	Oppositions to the issuance of patents may be filed under European patent law and the patent laws of certain other countries. As with USPTO interference proceedings, these foreign proceedings can be very expensive to contest and can result in significant delays in obtaining a patent or can result in a denial of a patent application.

	●	We might not be able to obtain any patents beyond those we already own or have licensed or sublicensed, and any patents that we do obtain might not be comprehensive enough to provide us with meaningful patent protection.

	●	There will always be a risk that our competitors might be able to successfully challenge the validity or enforceability of any patent issued to us.

	●	In addition to interference proceedings, the USPTO can reexamine issued patents at the request of a third party. Our patents may be subject to inter partes review (replacing the reexamination proceeding), a proceeding in which a third party can challenge the validity of one of our patents to have the patent invalidated. This means that patents owned or licensed by us may be subject to reexamination and may be lost if the outcome of the reexamination is unfavorable to us.

	●	The patents to which we have licenses to, including the licenses to HyStem are broadly licensed to other companies and in some instances, in overlapping fields of use. Asterias Biotherapeutics, Inc. (“Asterias”), a wholly-owned subsidiary of Lineage, has a non-exclusive license to HyStem patents in certain fields of use that overlap with the AgeX sublicensed fields of use. Asterias and AgeX may create competing products. In addition, AgeX, through our subsidiary ReCyte Therapeutics, is a sublicensee under a cross-license between Lineage and Asterias, which creates another potential risk of Asterias and AgeX creating competing products.

	●	a shift in our investor base;

	●	our quarterly or annual earnings, or those of comparable companies;

	●	actual or anticipated fluctuations in our operating results;

	●	our ability to obtain financing as needed;

	●	changes in laws and regulations affecting our business;

	●	changes in accounting standards, policies, guidance, interpretations or principles;

	●	announcements by us or our competitors of significant investments, acquisitions or dispositions;

	●	the failure of securities analysts to cover our common stock;

	●	changes in earnings estimates by securities analysts or our ability to meet those estimates;

	●	the operating performance and stock price of comparable companies;

	●	overall market fluctuations; and

	●	general economic conditions and other external factors.

	●	no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

	●	the ability of our Board of Directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; and

	●	the ability of our Board of Directors to alter our bylaws without obtaining stockholder approval.

	Year Ended December 31,				$ +Increase/		% +Increase/
	2022		2021		-Decrease		-Decrease
Grant revenues	$	-	$	104	$	-104	$	-100.0	%
Other revenues		34		40		-6		-15.0	%
Total revenues		34		144		-110		-76.4	%
Cost of sales		(13)		(19)		-6		-31.6	%
Gross profit	$	21	$	125	$	-104		-83.2	%

	Year Ended December 31,				$ +Increase/		% +Increase/
	2022		2021		-Decrease		-Decrease
Research and development expenses	$	1,025	$	1,456	$	-431		-29.6	%
General and administrative expenses		5,971		6,708		-737		-11.0	%

	Page Number
Report of Independent Registered Public Accounting Firm (PCAOB ID: 100)	73
Audited Consolidated Financial Statements:
Consolidated Balance Sheets	75
Consolidated Statements of Operations	76
Consolidated Statements of Comprehensive Loss	77
Consolidated Statements of Stockholders’ Deficit	78
Consolidated Statements of Cash Flows	79
Notes to Consolidated Financial Statements	80

/s/ WithumSmith+Brown, PC

We have served as the Company’s auditor since 2017.
San Francisco, California
March 31, 2023

PCAOB ID Number 100

	2022		2021
	December 31,
	2022		2021
ASSETS
Current assets:
Cash and cash equivalents	$	645	$	584
Accounts and grants receivable, net		4		25
Prepaid expenses and other current assets		1,804		1,625
Total current assets		2,453		2,234

Restricted cash		50		50
Intangible assets, net		738		870
TOTAL ASSETS	$	3,241	$	3,154

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued liabilities	$	1,034	$	771
Loan due to Juvenescence, net of debt issuance costs, current portion		7,646		7,140
Related party payables, net		141		70
Warrant liability		180		-
Insurance premium liability and other current liabilities		1,077		986
Total current liabilities		10,078		8,967

Loan due to Juvenescence, net of debt issuance costs, net of current portion		10,478		6,062
TOTAL LIABILITIES		20,556		15,029

Commitments and contingencies (Note 10)		-		-

Stockholders’ deficit:
Preferred stock, $0.0001 par value, 5,000 shares authorized; none issued and outstanding		-		-
Common stock, $0.0001 par value, 200,000 and 100,000 shares authorized, respectively; 37,949 and 37,941 shares issued and outstanding, respectively		4		4
Additional paid-in capital		98,994		93,912
Accumulated deficit		(116,210)		(105,748)
Total AgeX Therapeutics, Inc. stockholders’ deficit		(17,212)		(11,832)
Noncontrolling interest		(103)		(43)
Total stockholders’ deficit		(17,315)		(11,875)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	3,241	$	3,154

	Number of Shares		Par Value		Paid-In Capital		Accumulated Deficit			Noncontrolling Interest			Comprehensive Income		Stockholders’ Deficit
	Common Stock				Additional								Accumulated Other		Total
	Number of Shares		Par Value		Paid-In Capital		Accumulated Deficit			Noncontrolling Interest			Comprehensive Income		Stockholders’ Deficit
BALANCE AT DECEMBER 31, 2020		37,691	$	4	$	91,810	$	(97,073)		$	(280)		$	143	$	(5,396)

Issuance of common stock		242		-		475		-			-			-		475
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes		8		-		(7)		-			-			-		(7)
Issuance of warrants		-		-		757		-			-			-		757
Stock-based compensation		-		-		1,003		-			-			-		1,003
Transactions with noncontrolling interests – LifeMap Sciences		-		-		(269)		-			269			-		-
Deconsolidation of LifeMap Sciences		-		-		143		-			(22)			(143)		(22)
Fair value of liability classified warrants issued
Net loss		-		-		-		(8,675)			(10)			-		(8,685)
BALANCE AT DECEMBER 31, 2021		37,941		4		93,912		(105,748)			(43)			-		(11,875)
Balance		37,941		4		93,912		(105,748	)		(43	)		-		(11,875	)

Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes		8		-		(4)		-			-			-		(4)
Issuance of warrants		-		-		178		-			-			-		178
Fair value of liability classified warrants issued		-		-		4,148		-			-			-		4,148
Stock-based compensation		-		-		760		-			-			-		760
Net loss		-		-		-		(10,462)			(60)			-		(10,522)
BALANCE AT DECEMBER 31, 2022		37,949	$	4	$	98,994	$	(116,210)		$	(103)		$	-	$	(17,315)
Balance		37,949	$	4	$	98,994	$	(116,210	)	$	(103	)	$	-	$	(17,315	)


	Year Ended December 31,
REVENUES:	2022		2021
Grant revenues	$	-	$	104
Other revenues		34		40
Total revenues	$	34	$	144